Medios AG, a leading specialty pharma provider in Europe, has announced the appointment of Katrin Neuffer as Director of Investor Relations and Communications, effective immediately. Neuffer, who brings nearly two decades of experience in capital markets communications, will oversee the company's engagement with investors, analysts, and the media, succeeding Claudia Nickolaus.
Neuffer's career includes leadership roles at Wacker Neuson SE, where she managed investor relations and corporate communications from 2007 to 2018, guiding the company through its IPO and subsequent growth. She later served as Vice President at Exyte Group, preparing an IPO with a target market capitalization of over EUR 2 billion. Since 2020, she has advised listed companies on investor relations, IPO preparation, and crisis communications.
Thomas Meier, CEO of Medios AG, expressed confidence in Neuffer's ability to help reposition the company in the capital markets. "With Katrin Neuffer, we are gaining a proven capital markets expert who has guided publicly listed companies through decisive phases of development, from IPOs to strategic repositioning," he said. Meier also thanked Claudia Nickolaus for her years of service, noting her role in building the company's investor relations activities.
The appointment comes at a pivotal time for Medios, which is preparing for its upcoming Half-Year Financial Report on August 12, 2026, and its Capital Markets Day on September 28-29, 2026. These events will be crucial for the company to communicate its strategy and performance to the financial community.
Medios AG is Germany's first listed specialty pharmaceutical company, with shares traded on the Frankfurt Stock Exchange's Prime Standard and included in the SDAX index. The company operates across Germany, the Netherlands, Belgium, and Spain, focusing on individualized medicine to make innovative therapies accessible to patients.
As Medios continues to expand, Neuffer's experience in capital markets will be essential in fostering transparent communication and building investor confidence. Her appointment underscores the company's commitment to maintaining strong relationships with its stakeholders and navigating the complexities of the pharmaceutical market.
For more information about Medios AG and its services, visit www.medios.group. Details on individualized medicine can be found at app.medios.group/en/individualizedmedicine.
